AI firms are increasingly conducting virtual drug trials to predict the success of human studies, enhancing the likelihood that experimental medicines are effective and safe.

Artificial Intelligence is transforming the biopharmaceutical industry by accelerating drug discovery, enhancing personalized medicine, and making clinical trials more efficient, promising to bring ...

Small and mid-sized Indian pharmaceutical firms are witnessing a shift in orders from China to India due to cost and quality ...

The Gujarat-based company, which began as an agrochemicals supplier, has grown its pharma business from almost nil to about ...

AstraZeneca secures approval for camizestrant (Etcamah), an innovative breast cancer drug in India, promising an advanced ...

G, a new fixed-dose combination inhaler for the effective management of chronic obstructive pulmonary disease (COPD) in India ...

Eris Lifesciences appoints Chirag Mehta as Executive Director, overseeing international business, finance, and investor ...

Zydus Lifesciences, in collaboration with MSN Laboratories, has launched the first-ever generic version of Bayer's hypertension medication, Adempas (riociguat), in the US market, marking a significant ...

Aragen Life Sciences has unveiled Aragen OneHP, an integrated platform for developing and manufacturing peptides and antibody ...

Roche has entered a licensing agreement with Alector for an experimental Parkinson's disease treatment, AL050, for up to ...

Discover how Genmab and AbbVie's innovative blood cancer treatment, combining Epcoritamab with R-CHOP, has shown to ...

Indian pharmaceutical industry leaders emphasize the need for a strategic shift from generics to innovation, calling for increased investment in R&D, regulatory reforms, and an ecosystem conducive to ...